Hims & Hers Health Shares Rise on FDA Review of Compounded Peptide Therapies
Hims & Hers Health (NYSE:HIMS) rose 11.07% on April 16, 2026, following the FDA's decision to review compounded peptide therapies. The stock's increase was driven by potential regulatory changes that could allow the company to offer these therapies publicly. The broader market also saw modest gains, with the S&P 500 and Nasdaq Composite rising slightly.
Topics: FDA peptide_therapies regulatory_clearance stock_movement telehealth